Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epicatechin - Epirium Bio

Next Previous
Drug Profile

Epicatechin - Epirium Bio

Alternative Names: (+)- Epicatechin; EB-002; EPM-01

Latest Information Update: 28 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardero Therapeutics
  • Developer Epirium Bio; Mayo Clinic; University of California, Davis
  • Class Antibacterials; Benzopyrans; Catechols; Heart failure therapies; Small molecules
  • Mechanism of Action Mitochondrial protein modulators; Oxidoreductase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase II Friedreich's ataxia
  • No development reported Duchenne muscular dystrophy; Heart failure; Mitochondrial disorders

Most Recent Events

  • 01 Mar 2022 Epiruim Bio completes a phase I trial in Duchenne muscular dystrophy (In adolescents, In adults) in USA (PO) (NCT04386304)
  • 30 Sep 2020 No development reported - Phase-I/II for Duchenne muscular dystrophy (In adolescents, In children) in USA (PO)
  • 30 Sep 2020 No development reported - Phase-II for Duchenne muscular dystrophy (In adults) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top